Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small...
Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer
About this item
Full title
Author / Creator
Publisher
Tokyo: Springer Japan
Journal title
Language
English
Formats
Publication information
Publisher
Tokyo: Springer Japan
Subjects
More information
Scope and Contents
Contents
Background
We conducted a phase I dose escalation study to determine the maximum tolerated dose (MTD), the recommended dose (RD) and the safety profile of amrubicin (AMR) plus paclitaxel (PTX) combination regimen for patients with previously treated non-small cell lung cancer (NSCLC).
Patients and methods
PTX was administered at a fixed do...
Alternative Titles
Full title
Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1779345899
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1779345899
Other Identifiers
ISSN
1341-9625
E-ISSN
1437-7772
DOI
10.1007/s10147-015-0883-7
